Clinical Trial Update: An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

View source ↗

Summary

An observational time-and-motion study comparing subcutaneous and intravenous trastuzumab in HER2-positive early breast cancer has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Herceptin SC (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Status: COMPLETED | Results posted: 2016-03-25